The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr Landstedt-Hallin has been working as a clinician with a focus on diabetology for the majority of her professional career. She studied medicine at the Karolinska Institute (KI), Stockholm and received her MD in 1984. While studying for a PhD at KI, she also completed residencies in both Endocrinology/Diabetology and Internal Medicine.
She worked at the Danderyd University Hospital for over thirty years, where she was an investigator in local and multicentre studies, tutored PhD students, and also held administrative positions. Her latest published research was focused on real-world data regarding insulin degludec.
In 2013 Dr Landstedt-Hallin received the award of “Clinical diabetologist of the year” from her peers in the Swedish Association for Diabetologists (SFD). She is now semi-retired but continues to work clinically 1-2 days per week at a small hospital in Norrtälje, north of Stockholm, coaching people with type 1 diabetes.